Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Combo DAA treatments may benefit patients with resistant HCV genotype 3

Publish date:: November 23, 2020

Key clinical point: Combo treatment can be effective in achieving sustained virologic response (SVR) in patients with HCV genotype 3.

Major finding: The pooled SVR rate was 94.4% in treatment-naive patients and 88.0% in treatment-experienced patients.

Study details: Meta-analysis of 34 articles from Jan. 1, 2016, to Sept. 10, 2019, that examined the sustained virologic response (SVR) rate to DAA treatment.

Disclosures: The study was funded by the Chinese government and public institutions. The authors reported that they had no conflicts of interest.

Citation:

Zhuang L et al. Ann Hepatol. 2020 Oct 12. doi: 10.1016/j.aohep.2020.09.012.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

Must Reads in Infectious Diseases

Obesity, hypoxia predict severity in children with COVID-19,

Prophylactic HIV treatment in female STI patients is rare,

Combo DAA treatments may benefit patients with resistant HCV genotype 3,

Pronounced racial differences in HBsAg loss after stopping nucleos(t)ide,

Opt-out policy at a syringe service program increased HIV/HCV testing,